Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing NXP900, a small molecule drug candidate targeting solid tumor cancers. NXP900 inhibits SRC and YES1 kinases, which are aberrantly activated in many solid tumor cancers including breast, colon, prostate, pancreatic, ovarian, lung, head and neck, and esophageal cancers. NXP900 is currently in Phase 1b clinical trials, following Phase 1a completion in July 2025, where daily oral dosing was shown to be safe and tolerable with no dose-limiting toxicity reached. Phase 1b is evaluating NXP900 as a single agent and in combination with EGFR and ALK inhibitors, with a key use case being the reversal of resistance to established drugs like osimertinib and enzalutamide. Nuvectis licensed NXP900 from the University of Edinburgh in 2021, has no manufacturing facilities, and relies on third-party contract manufacturers. The company previously held a license for a second drug candidate, NXP800, but ceased development of that program in July 2025. Nuvectis generates no product revenue and funds operations through equity raises. The company has 13 full-time employees, and its cost structure is driven by outsourced clinical trial expenses and contract manufacturing. The path to value creation depends entirely on NXP900 achieving clinical and regulatory success.